Drug interactions
Erlotinib + Larotrectinib
Severity: Minor
Erlotinib and Larotrectinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Larotrectinib is a CYP3A4 substrate with possible weak inhibitory activity, so a small rise in erlotinib exposure is conceivable. Clinical significance is uncertain.
What this interaction means in plain words
Erlotinib and Larotrectinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Erlotinib belongs to Oncology; Larotrectinib belongs to Oncology.
Why it happens
Possible weak CYP3A4 inhibition by larotrectinib; the effect is not well established.
What to do
Monitor for erlotinib adverse effects such as rash and diarrhea and reduce the dose if needed.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Erlotinib and Larotrectinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Erlotinib
- Amobarbital + Erlotinib Major
- Apalutamide + Erlotinib Major
- Carbamazepine + Erlotinib Major
- Cobicistat + Erlotinib Major
- Darunavir + Erlotinib Major
- Dexlansoprazole + Erlotinib Major
Other interactions of Larotrectinib
Frequently asked questions
Can I take Erlotinib with Larotrectinib?
MediHelp rates the interaction as minor. Erlotinib and Larotrectinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Larotrectinib is a CYP3A4 substrate with possible weak inhibitory activity, so a small rise in erlotinib exposure is conceivable. Clinical significance is uncertain.
How serious is the interaction between Erlotinib and Larotrectinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for erlotinib adverse effects such as rash and diarrhea and reduce the dose if needed.
What other medicines interact with Erlotinib?
MediHelp also lists interactions of Erlotinib with, for example, Amobarbital, Apalutamide, Carbamazepine. The full list is on the Erlotinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
